Treatment of visceral leishmaniasis in children with liposomal amphotericin B

L. Di Martino, R. N. Davidson, R. Giacchino, S. Scotti, F. Raimondi, E. Castagnola, L. Tasso, A. Cascio, L. Gradoni, M. Gramiccia, M. Pettoello- Mantovani, A. D M Bryceson

Research output: Contribution to journalArticlepeer-review


We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

Original languageEnglish
Pages (from-to)271-277
Number of pages7
JournalJournal of Pediatrics
Issue number2
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Treatment of visceral leishmaniasis in children with liposomal amphotericin B'. Together they form a unique fingerprint.

Cite this